Text Size

Tolerability and pharmacokinetics of intravitreal sirolimus

Mudumba S., Bezwada P., Takanaga H., Hosoi K., Tsuboi T., Ueda K., Kawazu K., Ali Y., Naor J.


  • 2012
  • Journal of Ocular Pharmacology and Therapeutics
View publication
  • Therapeutic Area

    Back of the eye (BOTE)

  • Technology

    Pharmacology

  • Categories

    Preclinical development

  • Affiliations

    Pharmaceutical and Preclinical Development Department, Santen Incorporated, 2100 Powell Street, Emeryville, CA 94608, United States; Santen Pharmaceutical Co, Ltd., Ikoma-shi, Nara, Japan

Related Publications

Pyridylmethylthio derivatives as VEGF inhibitors. Part 1

Tajima H., Honda T., Kawashima K., Sasabuchi Y., Yamamoto M., Ban M., Okamoto K., Inoue K., Inaba T., Takeno Y., Aono H.


Consensus on evidence gaps and unmet needs in childhood myopia: findings from a European Delphi study with eye care professionals and payers

Lagreze W, Nucci P, Versteegh M, Klaver C, Barrio-Barrio J, Dahlmann-Noor A, Gomez de Liaño R, Ghorbani-Mojarrad N, Kessel L, Polling JR, Sauer A, Schuster AK, Serafino M, Villani E, Ziemssen F, Boehler YB, Capri S, Gianfrate F, Valles Callol JA, Wong O, Chen TY, Lymperopoulou C, Palaka I, Punekar Y, von Bredow D, Shi-van Wielink K.


Economic evaluation, resource utilisation, and associated economic burden of myopia management: a systematic literature review

de Milliano T. WL, Shi-van Wielink K., Ernst F., Mulkalapalli N., Pagidigummula R., Lymperopoulou C.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022